Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

297.23 +0.53 (+0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Via The Motley Fool
Topics Intellectual Property Stocks
Is the Market Bullish or Bearish on Amgen?
 
Via Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
Amgen Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Assessing Amgen: Insights From 9 Financial Analysts
 
Via Benzinga
Behind the Scenes of Amgen's Latest Options Trends
 
Via Benzinga
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026. 
Via Benzinga
Behind the Scenes of Amgen's Latest Options Trends
 
Via Benzinga
Prediction: These 2 Stocks Will Outperform the Market Through 2030
Via The Motley Fool
Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen
Via The Motley Fool
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year. 
Via Benzinga
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies. 
Via Benzinga
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
2 Reasons to Watch AMGN and 1 to Stay Cautious
Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period. 
Via StockStory
Topics Stocks
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
 
Via Benzinga
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial. 
Via Benzinga
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low. 
Via Benzinga
Topics ETFs Stocks
This Could Be the Best GLP-1 Stock to Buy in 2025
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Via The Motley Fool
Topics Stocks
Synchronicity: Denying The Unexplainable
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph? 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.